Ben R Taylor, Chief Financial Officer of Recursion Pharmaceuticals, Inc., filed a Form 4 on September 16, 2026, disclosing a transaction dated September 15, 2026, involving Class A Common Stock.

Key Highlights

  • Reporting person: Ben R Taylor, Chief Financial Officer of Recursion Pharmaceuticals, Inc.
  • Transaction date: September 15, 2026, involving Class A Common Stock.
  • Shares withheld: 5,396 shares disposed of (code F) at a price of $3.41 per share.
  • Purpose of transaction: Shares were withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
  • Beneficial ownership following transaction: 1,071,462 shares of Class A Common Stock held directly.

CFO Tax Withholding Transaction in Recursion Pharmaceuticals RSU Settlement

According to the filing, Ben R Taylor, serving as Chief Financial Officer of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), reported a single non-derivative securities transaction on September 15, 2026. The transaction code recorded is "F," which the filing's footnote explains represents shares withheld by the issuer rather than an open-market sale.

The filing states that 5,396 shares of Class A Common Stock were disposed of at a price of $3.41 per share. Per the explanation of responses included in the filing, these shares "have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units." Following this transaction, Taylor is reported to beneficially own 1,071,462 shares of Class A Common Stock directly.

No derivative securities transactions were reported in Table II of the filing. The Form 4 was filed by one reporting person and was signed by Kyle Nelson as attorney-in-fact on September 15, 2026. No amendment date was listed, indicating this is an original filing.

What Was Disclosed

The filing discloses a tax-related share withholding event in which 5,396 shares of Class A Common Stock were withheld at $3.41 per share upon RSU net settlement, leaving the CFO with direct beneficial ownership of 1,071,462 shares.